Table 5.
Antiviral activity of selected compounds against CMV and VZV in human embryonic lung (HEL) cells..
| Antiviral activity EC50a/μM |
Cytotoxicity/μM |
||||||
|---|---|---|---|---|---|---|---|
| Compd. |
R |
CMV |
VZV |
||||
| AD-169 | Davis | TK+ VZV (OKA) | TK− VZV (07/1) | Cell morphology (MCC)b | CC50c | ||
| 8b | Si(CH3)3 | >100 | 12.12 | >20 | >20 | 100 | 22.27 |
| 8k |  |
44.72 | >20 | >100 | >100 | 100 | NDd |
| 8l |  |
>20 | >4 | >20 | 7.31 | 20 | NDd |
| 8m |  |
>4 | >4 | 10.73 | 7.76 | 20 | NDd |
| 8n |  |
44.72 | >20 | >20 | 48.9 | 100 | NDd |
| 10d |  |
9.36 | 8.94 | >100 | 14.62 | 100 | >100 |
| 10e |  |
>100 | 8.94 | >100 | 44.72 | >100 | >100 |
| 10f |  |
8.94 | 5.66 | 27.59 | >4 | 20 | >100 |
| 10g |  |
20 | 5.74 | >100 | >100 | >100 | >100 |
| 10h |  |
>100 | 10.79 | >20 | >100 | 100 | 4.29 |
| 10i |  |
9.36 | 8.94 | 14.68 | 11.64 | 100 | 11.05 |
| 10n |  |
8.94 | 5.2 | 10.03 | 11.70 | 100 | 55.52 |
| 10p |  |
>100 | >100 | 78.06 | >100 | >100 | NDd |
| Ganciclovir | 3.15 | 2.3 | >350 | >350 | |||
| Cidofovir | 0.43 | 0.65 | >300 | 214 | |||
| Acyclovir | 1.56 | 96 | >440 | >440 | |||
| Brivudin | 0.0066 | 18.44 | >300 | 179 | |||
a
Effective concentration required to reduce virus plaque formation by 50%. Virus input was 100 plaque forming units (PFU).
b
Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology.
c
Cytotoxic concentration required to reduce cell growth by 50%.
d
Not determined.